Navigation Links
LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic,Protection Against Influenza Challenge With Virus-Like Particle,Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCyte Pharmaceuticals presented preclinical data today showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study. The company's data were presented by Dr. Joel Haynes, LigoCyte's senior director of vaccine development, at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation of Infectious Diseases in Baltimore.

The current influenza vaccination strategy involves immunization against hemagglutinin antigens that undergo continuous alteration in circulating influenza virus. Because the annual vaccines have to be manufactured in advance of influenza outbreaks, the unexpected emergence of a new or drifted subtype may result in a substantial reduction in protection.

LigoCyte's data show that immunization with their unique influenza H1N1-VLP formulation resulted in 100% protection against both H1N1 and H3N2 influenza challenge in preclinical studies. LigoCyte has also produced influenza VLPs carrying H3N2 and H5N1 antigens. H5N1 is the avian flu subtype that is currently circulating in bird populations and causing sporadic infections and death in humans.

"There is a great need for a universal influenza vaccine that simplifies manufacturing and delivery while enhancing protection against multiple viral subtypes," said Dr. Robert Bargatze, LigoCyte's chief scientific officer.

About LigoCyte:

LigoCyte, established in 1998, is developing a new generation of vaccines and monoclonal antibody therapeutics for the prevention and treatment of infectious diseases and inflammation. The company's investigational Norovirus vaccine for the prevention of acute gastroenteritis is currently in Phase I clinical studies. LigoCyte is advancing its other proprietary products into human clinical testing, positioning the company for continued growth an d success in the biotechnology industry. For additional information on LigoCyte, please visit Binding Science. Better Medicine.

This work is supported by the U.S. Army Medical Research and Material Command under Contract Nos. W8IXWH-05-C-0135. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985). In conducting work involving the use of recombinant DNA the investigator(s) adhered to Guidelines for Research Involving Recombinant DNA Molecules; Notice, Federal Register, July 5, 1994, Volume 59, Number 127.

CONTACT: Karen Sipes, Ph.D., Director, Marketing & Communications ofLigoCyte Pharmaceuticals, Inc., +1-406-556-9228,

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):